Amgen Inc. · NASDAQ:AMGN
Amgen — ESMO 2026
32 slides from Amgen's conference presentation, Oct 24, 2026
Slide 1: ESMO 2026 Update
ESMO 2026 UPDATE October 24, 2026
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outco
Slide 3: Agenda
Agenda Introduction Murdo Gordon, EVP, Global Markets & Policy Oncology Strategy and BiTE® Portfolio Jean-Charles Soria, SVP, Global Development, Oncology IMDELLTRA® Data Highlights from ESMO 2026 Dr. Charles Rudin, Director, Memorial Sloan Kettering Cancer Center Closing Remarks Jean-Charles Soria,
Slide 4: Today's Highlights
Today’s Highlights • Our BiTE® platform demonstrates transformative survival benefit in hematologic malignancies and solid tumors • IMDELLTRA® demonstrates durable survival benefit in small cell lung cancer • IMDELLTRA® is becoming the cornerstone therapy for ES-SCLC, regardless of combination choic
Slide 5: Amgen Has a Strong Portfolio of First-in-Class and Best-in-Class Medicines
Amgen Has a Strong Portfolio of First-in-Class and Best-in-Class Medicines Cardiovascular Disease Osteoporosis Severe Asthma Autoimmune Diseases Acute Lymphoblastic Leukemia Small Cell Lung Cancer Serving patient populations with significant unmet need Provided Oct. 24, 2026, as part of an oral pres
Slide 6: Amgen's Six Key Growth Drivers Grew 26% YoY in Q2 2026
Amgen’s Six Key Growth Drivers Grew 26% YoY in Q2 2026 and Comprised ~ 70% of Q2 Product Sales Q2 2026 Sales Growth (YoY) ~70% of Q2 Sales +37% +38% +42% generated by the six key growth drivers Rare Disease Innovative Biosimilars Oncology* +21% +18% +29% *Innovative Oncology Includes Blincyto®, Imde
Slide 7: Amgen's Oncology Strategy is Anchored in Two Core Pillars
Amgen’s Oncology Strategy is Anchored in Two Core Pillars IMMUNO-ONCOLOGY PRECISION THERAPIES Bispecific T-Cell Engagers Antibody-Drug Conjugates Small Molecules (BiTE®) (ADC) Fc Anti-CD3 Antibody Anti-DLL3 Linker & Payload T-cell mediated killing Combines the specificity of mAb with Cell-intrinsic
Slide 8: Amgen Has Pioneered Bispecific T-Cell Engager (BiTE) Medicines
Amgen Has Pioneered Bispecific T-Cell Engager (BiTE®) Medicines Where BiTE® Started BiTE® Medicines TODAY One transformative molecule: Multiple transformative molecules: BLINCYTO ® BLINCYTO ®, IMDELLTRA®, Xaluritamig (in Ph3) Hematologic malignancies Hematologic malignancies & solid tumors IV infusi
Slide 9: Xaluritamig Has the Potential to Extend the BiTE Platform into Prostate Cancer
Xaluritamig, in Phase 3 development, has the Potential to Extend the Impact of the BiTE® Platform into Prostate Cancer STEAP1 is a cell surface antigen, highly expressed in prostate cancer and associated with poor survival 1,2 Xaluritamig Mechanism of Action STEAP1 is Broadly Expressed3 mCRPC Normal
Slide 10: Xaluritamig is Being Investigated Across Multiple Disease Settings
Xaluritamig is Being Investigated Across Multiple Disease Settings Prostate Cancer Disease Progression Nonmetastatic Disease Metastatic Disease Chemo-Naïve Post-taxane (nmHSPC) (mHSPC) (mCRPC) (mCRPC) Localized Biochemical ADT Disease Recurrence Initiation Resistance to Resistance to Hormonal Tx Che
Slide 11: IMDELLTRA (tarlatamab-dlle)
IMDELLTRA® (tarlatamab-dlle)
Slide 12: Recent Advancements Have Generated Modest Improvements in Overall Survival in First-line SCLC
Recent Advancements have Generated Modest Improvements in Overall Survival in First-line Small Cell Lung Cancer Phase 3 Phase 3 Phase 3 IMpower133 CASPIAN IMforte Atezolizumab IMFINZI® (durvalumab) Atezolizumab + Chemo + Chemo + Lurbinectedin in 1L ES-SCLC1 in 1L ES-SCLC2 in 1LM ES-SCLC3 What will I
Slide 13: IMDELLTRA Plus a PD-L1 Delivered 37.9 Months of Survival in SCLC (DeLLphi-303)
IMDELLTRA® Plus a PD-L1 Delivered 37.9 Months of Survival in SCLC in a Phase 1b First-Line Maintenance Study (DeLLphi-303) Overall survival with IMDELLTRA® + anti-PD-L1 as 1L maintenance therapy from Phase 1b DeLLphi-303 • Median OS for patients with ES-SCLC Overall IMDELLTRA® + treated in 1L mainte
Slide 14: DeLLphi-305 Primary Analysis of the Phase 3 Trial
IMDELLTRA® plus IMFINZI® vs IMFINZI® as first-line maintenance therapy following first-line IMFINZI®, platinum, and etoposide in extensive-stage small cell lung cancer: primary analysis of the phase 3 DeLLphi-305 trial Jacob Sands, Tatsuya Yoshida, Myung-Ju Ahn, Carl M. Gay, Martin Schuler, Haifeng
Slide 15: DeLLphi-305 Study Design
DeLLphi-305 Study Design A Phase 3, Open-label, Multicenter, Randomized Study of IMDELLTRA® in Combination With IMFINZI® vs IMFINZI ® Alone in Patients With ES-SCLC Following Platinum, Etoposide and IMFINZI® (NCT06211036) Treatment until progression or unacceptable toxicity 1L Chemo-IO Key Inclusion
Slide 16: Baseline Characteristics
Baseline Characteristics IMDELLTRA® + IMFINZI® IMFINZI® Characteristics (n = 282) (n = 281) Age, median (range), years 65.0 (35–87) 65.0 (29–86) Male, % 69.9 71.5 Race, White/Non-white, % 57.8 / 42.2 64.4 / 35.6 Region, Americas/Asia-Pacific/Europe, % 12.8 / 40.4 / 46.8 13.9 / 35.9 / 50.2 ECOG PS, 0
Slide 17: IMDELLTRA Plus IMFINZI Significantly Improved Overall Survival
IMDELLTRA® Plus IMFINZI® Significantly Improved Overall Survival Versus IMFINZI® Alone as First-line Maintenance Therapy IMDELLTRA® + IMFINZI® IMFINZI® (n = 282) (n = 281) Median OS, months (95% CI) 21.1 (20.8–NE) 12.7 (11.2–14.8) Median FU, months 15.9 16.1 100 92% HR (95% CI); P-value (2-sided)a 0
Slide 18: OS Benefit Was Consistent Across All Key Prespecified Subgroups
OS Benefit Was Consistent Across All Key Prespecified Subgroups Subgroup IMDELLTRA® + IMFINZI ® IMFINZI® Hazard Ratio for Death no. of events / no. of patie nts (95% CI) Age < 65 years 34 / 139 69 / 133 0.36 (0.24–0.54) ≥ 65 years 53 / 143 87 / 148 0.48 (0.34–0.67) Sex Male 64 / 197 120 / 201 0.38 (
Slide 19: IMDELLTRA Plus IMFINZI Significantly Improved PFS Versus IMFINZI Alone
IMDELLTRA® Plus IMFINZI® Significantly Improved PFS Versus IMFINZI® Alone IMDELLTRA® + IMFINZI® IMFINZI® (n = 282) (n = 281) 100 Median PFS, months (95% CI) 7.4 (5.6–9.1) 1.9 (1.9–2.0) Median FU, months 13.9 13.9 80 Percentage of Patients HR (95% CI); P-value (2-sided)a 0.34 (0.28–0.42); P < 0.001 6
Slide 20: PFS Favored IMDELLTRA Plus IMFINZI Across Prespecified Subgroups
PFS Favored IMDELLTRA® Plus IMFINZI® Across Prespecified Subgroups Subgroup IMDELLTRA® + IMFINZI ® IMFINZI ® Hazard Ratio for Disease no. of events / no. of patients Progression or Death (95% CI) Age < 65 years 86 / 139 119 / 133 0.32 (0.24–0.42) ≥ 65 years 96 / 143 131 / 148 0.38 (0.29–0.50) Sex Ma
Slide 21: Significantly Improved Objective Response Rate Versus IMFINZI Alone
IMDELLTRA® Plus IMFINZI® Demonstrated Significantly Improved Objective Response Rate Versus IMFINZI® Alone IMDELLTRA® + IMFINZI ® IMFINZI ® Duration of response (n = 235)a (n = 244)a 100 BOR, n (%)a,b 70% Progression or Death Responders Without 80 Confirmed CRc 2 (0.9) 1 (0.4) 52% IMDELLTRA ® + 60 I
Slide 22: Manageable Safety Profile Consistent with the Individual Agents
IMDELLTRA® Plus IMFINZI® Showed a Manageable Safety Profile Consistent with the Individual Agents IMDELLTRA® + IMFINZI® IMFINZI® (n = 282) (n = 278) Median duration of treatment, weeks (IQR) 46.9 (16.4–65.6) 8.1 (4.1–20.1) Any grade TEAEs, n (%) 281 (99.6) 258 (92.8) Grade ≥ 3, n (%) 132 (46.8) 113
Slide 23: CRS and ICANS Events Profile Consistent with Known Safety Profile
CRS and ICANS Events Profile is Consistent with The Known Safety Profile of IMDELLTRA® IMDELLTRA® IMDELLTRA® CRSa,b, n (%) + IMFINZI® IMFINZI® ICANSd, n (%) + IMFINZI® IMFINZI® (n = 282) (n = 278) (n = 282) (n = 278) Any grade 140 (49.6) 4 (1.4) Any grade 3 (1.1) 0 (0.0) Grade 2 21 (7.4) 2 (0.7) Gra
Slide 24: Conclusions
Conclusions • IMDELLTRA® plus IMFINZI® significantly improved OS, PFS, and ORR versus IMFINZI ® alone in patients with ES-SCLC without progression after initial chemo plus IMFINZI® o 58% reduction in the risk of death; P < 0.001 o 66% reduction in the risk of disease progression or death; P < 0.001
Slide 25: Simultaneously Published in the New England Journal of Medicine
Simultaneously Published in the New England Journal of Medicine Provided Oct. 24, 2026, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. 25
Slide 26: Acknowledgements
Acknowledgements We gratefully acknowledge Ying Cheng, M.D. (Jilin Cancer Hospital, Changchun, China), for her contributions as the China leading principal investigator and scientific leadership. We thank all the patients, their families, the DeLLphi-305 investigators, and clinical site Copies of th
Slide 27: Pursuing a Broad Clinical Development Program to Establish IMDELLTRA as Cornerstone Therapy
Pursuing a Broad Clinical Development Program to Establish IMDELLTRA® as the Cornerstone Therapy in SCLC Phase 1b Phase 2 Phase 3 1LM Phase 3 (DeLLphi-305) 21.1 months (est. mOS)1 TRANSFO RM 1LM Phase 1b (DeLLphi-303) 37.9 months (mOS)2 FRO NTLINE SURVIVAL 1L Phase 3 (DeLLphi-312) Enrollment Complet
Slide 28: IMDELLTRA: The Established Standard of Care in 2L+ ES-SCLC
IMDELLTRA®: The Established Standard of Care in 2L+ ES-SCLC Revolutionized Survival Approved in 50+ Significant Opportunity in 2L+ ES-SCLC Markets Globally Remains in the 2L+ Setting • Extending the median overall • Over 18K patients treated • Chemotherapy remains a survival by more than five since
Slide 29: Moving IMDELLTRA Earlier in the SCLC Treatment Continuum
Moving IMDELLTRA® Earlier in the SCLC Treatment Continuum Extensive Stage SCLC Become An Established SOC in 2L+ Limited Stage (LS) SOC in First-Line (1L) ~14K ~23K •~5K + Eligible U.S. patients Eligible U.S. patients Eligible U.S. patients 1LM Phase 3 combination with LS Phase 3 Monotherapy vs PD-L1
Slide 30: IMDELLTRA Has Demonstrated Transformative Overall Survival in First-line SCLC
IMDELLTRA® has Demonstrated Transformative Overall Survival in First-line Small Cell Lung Cancer IMDELLTRA® Clinical Trials Phase 3 Phase 3 Phase 3 1LM Phase 3 IMDELLTRA ® 1LM Phase 1b IMDELLTRA ® IMpower133 CASPIAN IMforte + IMFINZI® (DeLLphi-305)4,5 + PD-L1 (DeLLphi-303)6 Atezolizumab IMFINZI® (du
Slide 31: IMDELLTRA is Revolutionizing the Treatment of Small Cell Lung Cancer
IMDELLTRA® is Revolutionizing the Treatment of Small Cell Lung Cancer Across Multiple Dimensions of Care UNPRECEDENTED FUTURE DOSING CORNERSTONE BIOSIMILARS DURABLE SURVIVAL IMPROVEMENTS THERAPY 1LM Phase 3 (DeLLphi-305)1 On-site monitoring for 21.1 months 6 to 8 hours Broad Clinical Est. Median Ove
Slide 32: Q&A
Q&A Provided Oct. 24, 2026, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. 32